Portola Pharma (PTLA) Misses Q1 EPS by 5c

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($0.74), $0.05 worse than the analyst estimate of ($0.69). Revenue for the quarter came in at $5.13 million versus the consensus estimate of $20.46 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18